Ibritumomab tiuxetan
Radioimmunotherapy treatment / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Ibritumomab tiuxetan?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Ibritumomab tiuxetan (pronounced /ɪbrɪˈtuːmoʊmæb taɪˈʌksɛtæn/[1]), sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's lymphoma. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope (either yttrium-90 or indium-111) is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group.[2][3]
Quick Facts Monoclonal antibody, Type ...
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | CD20 |
Clinical data | |
Trade names | Zevalin |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | intravenous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank |
|
ChemSpider |
|
UNII | |
ChEMBL | |
NY (what is this?) (verify) |
Close